Optomed Plc’s ten largest shareholders after the completion of the Initial Public Offering
OPTOMED PLC STOCK EXCHANGE RELEASE 11 December 2019 at 8.45 a.m.
Optomed Plc’s ten largest shareholders after the completion of the Initial Public Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
The ten largest registered shareholders of Optomed Plc (“Optomed” or the “Company”) and their shares of ownership after the Initial Public Offering (the “Offering”) based on the shareholders’ register maintained by Euroclear Finland Oy are shown in the table below. Shareholders’ holdings are presented based on information from the shareholders’ register as at 9 December 2019 and the ten largest shareholders do not include the shareholders that are nominee registered. The nominee registered shareholders hold approximately 36.3 % of total shares.
| Shareholder | Number of shares | % of total shares |
| Aura Capital Oy | 691,756 | 4.94 |
| Seppo Kopsala | 637,080 | 4.55 |
| Mandatum Life Insurance Company Limited | 635,000 | 4.53 |
| Finnish Industry Investment Ltd | 601,080 | 4.29 |
| Sijoitusrahasto Nordea Nordic Small Cap | 500,000 | 3.57 |
| Kaleva Mutual Insurance Company | 490,000 | 3.50 |
| Sijoitusrahasto Aktia Capital | 400,000 | 2.86 |
| OP-Suomi Pienyhtiöt | 335,000 | 2.39 |
| Sijoitusrahasto Aktia Nordic Micro Cap | 260,000 | 1.86 |
| Veritas Pension Insurance Company Ltd. | 130,000 | 0.93 |
| Ten largest, in total | 4,679,916 | 33.42 |
| Other shareholders | 9,323,228 | 66.58 |
| of which nominee-registered shares | 5,084,622 | 36.31 |
| of which treasury shares | 811,000 | 5.79 |
| Total | 14,003,144 | 100.0 |
The following table sets forth the ten largest shareholders of the Company before the Offering.
| Shareholder | Number of shares | % of total shares |
| Cenova Capital (China)1 | 2,438,280 | 25.51 |
| Alnair Investments | 1,142,800 | 11.96 |
| Cenova China Healthcare Fund IV | 895,480 | 9.37 |
| Shanghai Cenova Innovation Venture Fund (Limited Partnership) | 400,000 | 4.18 |
| Halma Ventures Limited2 | 1,900,680 | 19.88 |
| Robert Bosch Venture Capital GmbH | 1,106,920 | 11.58 |
| Aura Capital Oy3 | 1,064,240 | 11.13 |
| Finnish Industry Investment Ltd4 | 801,440 | 8.38 |
| Seppo Kopsala | 637,080 | 6.66 |
| Mankato Capital Ltd5 | 322,280 | 3.37 |
| Cliff Swallow Investment Ltd | 265,160 | 2.77 |
| Ten largest, in total | 8,536,080 | 89.30 |
| Other shareholders | 1,022,620 | 10.70 |
| of which treasury shares | 811,000 | 8.48 |
| Total | 9,558,700 | 100.00 |
| __________________________________ |
| 1) Alnair Investments, Cenova China Healthcare Fund IV and Shanghai Cenova Innovation Venture Fund (Limited Partnership) are controlled by Cenova Capital (China), an entity controlled by Jun Wu. 2) The number of shares sold by Halma Ventures Limited in the Offering amounts to 978,628 shares. The Company received on 9 December 2019 a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Market Act from Halma plc, according to which the total holdings in the Company shares and votes indirectly held by Halma plc (directly held by Halma Ventures Limited) decreased to 0 percent of all the registered shares in the Company on 5 December 2019. The change in the position was due to a share lending agreement entered into between Halma Ventures Limited and Carnegie Investment Bank AB (publ) (“Carnegie”) on 5 December 2019, according to which Carnegie has borrowed 922,052 shares in the Company on 5 December 2019. 3) The number of shares sold by Aura Capital Oy in the Offering amounts to 372,484 shares. 4) The number of shares sold by Finnish Industry Investment Ltd in the Offering amounts to 200,360 shares. 5) Mankato Capital Ltd is controlled by Anders Torstensson. The number of shares sold by Mankato Capital Ltd in the Offering amounts to 96,683 shares. |
Further enquiries
Seppo Kopsala, CEO, Optomed Plc, tel. +358 40 555 1050, seppo.kopsala@optomed.com
Lars Lindqvist, CFO, Optomed Plc, lars.lindqvist@optomed.com
Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com
Distribution
Nasdaq Helsinki Ltd
Principal media
www.optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 52 international patents protecting the technology. In 2018, Optomed’s revenue reached EUR 12.7 million and pro forma revenue with the acquisition of Commit; Oy amounted to EUR 14.5 million. At the end of September 2019, Optomed employed 105 professionals.
Disclaimer
It may be unlawful to distribute this announcement in certain jurisdictions. This announcement is not for distribution in Australia, Canada, the Hong Kong special administrative region of the People’s Republic of China, Japan, New Zealand, Singapore, South Africa, the United States or to any other jurisdiction where such distribution would be unlawful. The information in this announcement does not constitute an offer of securities for sale in such jurisdictions.
This announcement does not constitute an offer for sale of, or a solicitation of an offer to purchase or subscribe for, any securities in the United States. Securities may not be offered or sold in the United States unless they are registered or are exempt from registration under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. Optomed Plc (the “Company”) does not intend to register any portion of this offering in the United States or to conduct a public offering in the United States. Copies of this announcement are not being, and should not be, distributed in or sent into the United States.
The issue and/or sale of securities in connection with the contemplated listing on the official list of Nasdaq Helsinki Ltd (the “Listing”) are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company, Carnegie Investment Bank AB (publ) (“Carnegie”) and Swedbank AB (publ) (“Swedbank”) assume no responsibility in the event there is a violation by any person of such restrictions.
In the United Kingdom, this announcement is for distribution only to and is directed only at persons who (i) have professional experience in matters relating to investments which fall within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Financial Promotion Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc”) of the Financial Promotion Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area, other than Finland or Sweden, where Regulation (EU) 2017/1129 (the “Prospectus Regulation”) is applicable (each, a “Relevant Member State”), will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of securities. As a result, the securities may only be offered in Relevant Member States (a) to “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation; or (b) in any other circumstances falling within Article 1(4) of the Prospectus Regulation. Neither the Company nor any of the Managers have authorised, nor do they authorise, the making of any offer of the securities through any financial intermediary, other than offers made by the Managers which constitute the final placement of the securities contemplated in this announcement. Neither the Company nor any of the Managers have authorised, nor do they authorise, the making of any offer of securities in circumstances in which an obligation arises for the Company or any Managers to publish or supplement a prospectus for such offer.
The information contained in this announcement is for informational purposes only and does not purport to be full or completed. No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness. This announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefor. The information in this announcement is subject to change. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published by the Company and available on the Company’s website www.optomed.com/ipo.
Carnegie and Swedbank are acting exclusively for the Company and the Selling Shareholders and for no-one else in connection with any transaction mentioned in this announcement and will not regard any other person (whether or not a recipient of this announcement) as a client in relation to any such transaction and will not be responsible to any other person for providing the protections afforded to their clients, or for advising any such person on the contents of this announcement or in connection with any transaction referred to in this announcement. The contents of this announcement have not been verified by Carnegie or Swedbank and neither Carnegie nor Swedbank accept liability for this information included in this announcement.